FDA Approves Theranica’s Nerivio® for Acute Treatment of Migraine in Adolescents

The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above

NETANYA, Israel and MONTCLAIR, N.J., Jan. 25, 2021 /PRNewswire/ — Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the treatment of adolescents is supported by a study recently published in Headache. Read more…